DK0633931T3 - Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon - Google Patents

Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon

Info

Publication number
DK0633931T3
DK0633931T3 DK93907858T DK93907858T DK0633931T3 DK 0633931 T3 DK0633931 T3 DK 0633931T3 DK 93907858 T DK93907858 T DK 93907858T DK 93907858 T DK93907858 T DK 93907858T DK 0633931 T3 DK0633931 T3 DK 0633931T3
Authority
DK
Denmark
Prior art keywords
interferon
monoclonal antibodies
activity against
neutralizing activity
against type
Prior art date
Application number
DK93907858T
Other languages
Danish (da)
English (en)
Inventor
Michael G Tovey
Patrick Benoit
Debborah Maguire
Ivan Plavec
Francois Meyer
Original Assignee
Medisup Internat N V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medisup Internat N V filed Critical Medisup Internat N V
Application granted granted Critical
Publication of DK0633931T3 publication Critical patent/DK0633931T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7156—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Transplantation (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK93907858T 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon DK0633931T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP92400902A EP0563487A1 (de) 1992-03-31 1992-03-31 Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
PCT/EP1993/000770 WO1993020187A1 (en) 1992-03-31 1993-03-30 Monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon

Publications (1)

Publication Number Publication Date
DK0633931T3 true DK0633931T3 (da) 2003-09-15

Family

ID=8211644

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93907858T DK0633931T3 (da) 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon
DK02028948T DK1329459T3 (da) 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK02028948T DK1329459T3 (da) 1992-03-31 1993-03-30 Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon

Country Status (18)

Country Link
US (5) US5919453A (de)
EP (3) EP0563487A1 (de)
JP (2) JP3836500B2 (de)
AT (2) ATE368055T1 (de)
AU (2) AU679909B2 (de)
BG (1) BG99141A (de)
CA (1) CA2133106C (de)
CZ (1) CZ236994A3 (de)
DE (2) DE69332997T2 (de)
DK (2) DK0633931T3 (de)
ES (2) ES2290241T3 (de)
FI (1) FI944509A7 (de)
HU (1) HUT69995A (de)
NO (1) NO943625L (de)
NZ (1) NZ251343A (de)
PT (2) PT633931E (de)
RU (1) RU94045826A (de)
WO (1) WO1993020187A1 (de)

Families Citing this family (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0563487A1 (de) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
CA2171955A1 (en) * 1993-09-17 1995-03-23 Michael G. Tovey Pharmaceutical composition comprising monoclonal antibodies against the interferon receptor, with neutralizing activity against type i interferon
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor
US6713609B1 (en) 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
CN1068524C (zh) * 1997-06-23 2001-07-18 叶庆炜 一种治疗顽症牛皮癣的药物
US6376067B1 (en) * 1998-12-21 2002-04-23 Mitsubishi Polyester Film, Llc Silicone coated film with back side slip control coating and method of controlling slip of such film
GB0001712D0 (en) * 2000-01-25 2000-03-15 Pharma Pacific Pty Ltd Therapeutic peptides
AU2007202840B2 (en) * 2001-01-09 2011-07-28 Baylor Research Institute Methods for treating autoimmune diseases in a subject and in vitro diagnostic assays
DE60239522D1 (de) * 2001-01-09 2011-05-05 Baylor Res Inst Dallas Verfahren zur behandlung von autoimmunerkrankungen bei einem probanden und diagnostische in-vitro-assays
US7087726B2 (en) * 2001-02-22 2006-08-08 Genentech, Inc. Anti-interferon-α antibodies
EP1631590B1 (de) * 2003-04-23 2011-07-27 Medarex, Inc. Humanisierte antikörper gegen interferon-alpha-rezeptor-1 (ifnar-1)
PL1631312T3 (pl) * 2003-04-23 2009-02-27 Squibb & Sons Llc Kompozycje i sposoby terapii choroby zapalenia jelit
AU2007203559B2 (en) * 2003-04-23 2010-09-02 E. R. Squibb & Sons, L.L.C. Compositions and methods for the therapy of inflammatory bowel disease
IN2009KN02655A (de) 2003-12-10 2015-10-23 Medarex Inc
AU2005250369A1 (en) * 2004-05-18 2005-12-15 Genentech, Inc. M13 virus major coat protein variants for C-terminal and BI-terminal display of a heterologous protein
RU2412202C2 (ru) 2004-06-21 2011-02-20 Медарекс, Инк. Антитела рецептора 1 интерферона альфа и их применение
MX2007003809A (es) * 2004-10-07 2007-09-12 Univ Zuerich Agentes bloqueadores de interferon tipo i para prevencion y tratamiento de soriasis.
US7888481B2 (en) * 2005-02-10 2011-02-15 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
WO2006086586A2 (en) * 2005-02-10 2006-08-17 Baylor Research Institute Anti-interferon alpha monoclonal antibodies and methods for use
EP1893646A2 (de) * 2005-06-22 2008-03-05 Genentech, Inc. Verfahren und zusammensetzungen für ifnar2-targeting
EP2687232A1 (de) 2006-12-06 2014-01-22 MedImmune, LLC Verfahren zur Behandlung von systemischem Lupus erythematodes
US8685400B2 (en) 2007-07-30 2014-04-01 University Of Miami Modulating inflammasome activity and inflammation in the central nervous system
MX2010008578A (es) 2008-02-08 2010-11-10 Medimmune Llc Anticuerpos anti-receptor 1 de interferon alfa con afinidad reducida al ligando fc.
WO2009135861A2 (en) 2008-05-07 2009-11-12 Novo Nordisk A/S Humanized antibodies against human interferon-alpha
RU2015145543A (ru) * 2010-03-01 2019-01-11 Алексион Фармасьютикалз Инк. Способы и композиции для лечения болезни дего
WO2013134146A1 (en) * 2012-03-07 2013-09-12 The Regents Of The University Of California Methods and compositions for treating viral infections by blocking type i interferon activity
EP4410378A3 (de) 2016-07-01 2024-10-09 Resolve Therapeutics, LLC Optimierte binucleasefusionen und verfahren
CN108409862B (zh) 2016-07-14 2021-07-13 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
MX2020002070A (es) 2017-08-22 2020-03-24 Sanabio Llc Receptores solubles de interferon y usos de los mismos.
CN113728006B (zh) * 2019-01-31 2022-10-14 广东旋玉健康生物科技有限公司 新型抗ifnar1抗体
CN117500816B (zh) 2021-08-26 2025-03-28 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
CN115028730B (zh) * 2022-05-17 2022-11-08 诺赛联合(北京)生物医学科技有限公司 一种成体干细胞衍生的类器官制备方法

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2953132A (en) 1955-10-27 1960-09-20 Baxter Laboratories Inc Parenteral solution equipment
US3066671A (en) 1959-10-27 1962-12-04 Milton J Cohen Disposable additive container
US3608550A (en) 1969-05-07 1971-09-28 Becton Dickinson Co Transfer needle assembly
BE791340A (fr) 1972-01-06 1973-03-01 Becton Dickinson Co Nouveaux procede et appareil de prelevement de culture et d'identification de micro-organismes des humeurs
US4024857A (en) 1974-12-23 1977-05-24 Becton, Dickinson And Company Micro blood collection device
US4300404A (en) 1977-12-01 1981-11-17 Becton, Dickinson And Company Liquid specimen container
US4116066A (en) 1977-12-12 1978-09-26 Becton, Dickinson And Company Specimen sampler cup
US5516515A (en) * 1986-02-05 1996-05-14 Interferon Sciences, Inc. Separation of alpha interferon receptor proteins and antibodies therefor
IL88377A (en) * 1988-11-14 1996-09-12 Yeda Res & Dev Cloning and expression of a protein which modulates cellular response to type I interferon
US5889151A (en) * 1989-10-20 1999-03-30 Societe Leb-Tech Purified human alpha interferon receptor
FR2653445B1 (fr) * 1989-10-20 1994-07-29 Centre Nat Rech Scient Fragment d'adnc codant pour le gene du recepteur de l'interferon alpha et procede de preparation d'une proteine correspondante.
GB8928874D0 (en) * 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
FR2657881A1 (fr) * 1990-02-05 1991-08-09 Europ Biotechnologie Lab Nouveaux polypeptides hydrosolubles, sequences d'adn, nouvelles cellules, procede de preparation, applications et compositions renfermant lesdits polypeptides.
IL99232A0 (en) * 1990-08-20 1992-07-15 Univ Columbia Methods for producing rna viruses from cdna
EP0537166B1 (de) * 1991-04-17 1999-07-07 Medisup International N.V. Neue wasserlösliche polypeptide mit hoher affinität für alpha- und beta- interferone
EP0563487A1 (de) 1992-03-31 1993-10-06 Laboratoire Europeen De Biotechnologie S.A. Monoklonale Antikörper gegen den Interferonrezeptor, mit neutralisierender Aktivität gegen Typ I-Interferon
EP0671926B1 (de) * 1992-08-11 2002-11-13 President And Fellows Of Harvard College Immunmodulierende peptide
CA2148907C (en) * 1992-12-29 2008-07-08 Rebecca H. R. Ward Treatment of inflammatory bowel disease with ifn-gamma inhibitors
ES2186714T3 (es) * 1994-03-07 2003-05-16 Imperial College Uso de sustipo simple alpha 8 en la preparacion de medicamentos para el tratamiento de infecciones virales del higado.
IL118096A0 (en) * 1996-05-01 1996-09-12 Yeda Res & Dev Antibodies against interferon alpha/beta receptor

Also Published As

Publication number Publication date
WO1993020187A1 (en) 1993-10-14
EP1329459A2 (de) 2003-07-23
NZ251343A (en) 1997-07-27
EP0633931B1 (de) 2003-05-21
US5919453A (en) 1999-07-06
PT1329459E (pt) 2007-11-07
DK1329459T3 (da) 2007-11-26
FI944509L (fi) 1994-11-29
AU3890793A (en) 1993-11-08
US6787634B2 (en) 2004-09-07
NO943625D0 (no) 1994-09-29
CA2133106A1 (en) 1993-10-14
US7179465B2 (en) 2007-02-20
EP1329459B1 (de) 2007-07-25
US7465451B2 (en) 2008-12-16
CA2133106C (en) 2009-06-30
ATE368055T1 (de) 2007-08-15
CZ236994A3 (en) 1995-02-15
US20070128701A1 (en) 2007-06-07
DE69332997D1 (de) 2003-06-26
AU679909B2 (en) 1997-07-17
JP3836500B2 (ja) 2006-10-25
RU94045826A (ru) 1996-11-10
ES2290241T3 (es) 2008-02-16
US20080226647A1 (en) 2008-09-18
US20020055492A1 (en) 2002-05-09
DE69332997T2 (de) 2004-05-19
EP1329459A3 (de) 2003-09-10
DE69334158D1 (de) 2007-09-06
BG99141A (bg) 1995-07-28
ES2199941T3 (es) 2004-03-01
JP2006089494A (ja) 2006-04-06
AU2349697A (en) 1997-07-24
EP0633931A1 (de) 1995-01-18
JPH07505526A (ja) 1995-06-22
FI944509A0 (fi) 1994-09-29
US20040191840A1 (en) 2004-09-30
NO943625L (no) 1994-11-11
DE69334158T2 (de) 2008-04-10
ATE241008T1 (de) 2003-06-15
AU706473B2 (en) 1999-06-17
PT633931E (pt) 2003-09-30
EP0563487A1 (de) 1993-10-06
FI944509A7 (fi) 1994-11-29
HUT69995A (en) 1995-09-28
HU9402823D0 (en) 1995-01-30

Similar Documents

Publication Publication Date Title
DK0633931T3 (da) Monoklonale antistoffer mod interferonreceptorer, hvilke antistoffer har neutraliserende aktivitet over for type I-interferon
ATE141329T1 (de) Rekombinante antikörper spezifisch für einen wachstumsfaktor-rezeptor
BR0315123A (pt) Composições farmacêuticas direcionadas a receptores erb-b1
DE122008000030I1 (de) Therapeutische Zusammensetzungen die monoklonale Antikörper enthalten gegen den menschlichen Rezeptor für epidermalen Wachstumsfaktor
ATE348157T1 (de) Menschliche toll-ähnliche rezeptorproteine, zugehörige reagenzien und verfahren
DE69634079D1 (de) Antagoniste des vasculären endothelzellewachstumfaktors
FR15C0076I2 (fr) Molecules de liaison d'antigene avec affinite de liaison de recepteur fc amelioree et fonction d'effecteur
EP1625209A4 (de) Chimärische immunglobulin-monomer-dimer-hybride
TR200202254T2 (tr) IL-18 Kaynaklı rahatsızlıkların tedavisinde faydalı rekombinant IL-18 antagonistleri.
EA200300464A1 (ru) ГУМАНИЗИРОВАННОЕ АНТИТЕЛО ПРОТИВ РЕЦЕПТОРА ЛИМФОТОКСИНА-β (ВАРИАНТЫ), КОМПОЗИЦИЯ, СПОСОБ ЛЕЧЕНИЯ ИЛИ СНИЖЕНИЯ РИСКА РАЗВИТИЯ, ТЯЖЕСТИ ИЛИ ПОСЛЕДСТВИЙ НЕОПЛАЗИИ У ЧЕЛОВЕКА, ВЫДЕЛЕННАЯ НУКЛЕИНОВАЯ КИСЛОТА (ВАРИАНТЫ), КЛЕТКА КЛЕТОЧНОЙ ЛИНИИ
KR930000538A (ko) 4가의 이특이적 수용체, 이의 제조방법 및 이의 용도
TR200200781T1 (tr) Birlikte uyaran bir sinyal transdüksiyon molekülü olan ailime karşı insan monoklonal antikoru ve bunun farmasötik kullanımı
DE60042693D1 (de) Dosierung für die behandlung mit anti erbb2-antikörpern
NZ324500A (en) Humanized antibodies to human gp39, compositions containing and therapeutic use thereof
DE60226499D1 (de) Verwendung von antikörpern gegen das muc18-antigen
ATE121299T1 (de) Antigene epitope, die sich ausschliesslich auf ige-tragenden b-lymphocyten befinden.
KR970703368A (ko) CD44v6에 대한 모노클로날 항체(Monoclonal antibody active against CD44v6)
PT1011723E (pt) Factor de crescimento tumorigenico de 88 kda e antagonistas
EP0583050A3 (de) Rekombinanter, stimulierender Faktor für den "neu"-Rezeptor.
EE05497B1 (et) Polüpeptiid, lahustuv CRAM-1 polüpeptiid, polünukleotiid ja antikeha
EP0948536A4 (de) G-protein gekoppelter rezeptor mit vergrösserter, extrazellulärer domäne
EP0858505A4 (de) Klonierung von pheromon rezeptoren aus vertebraten und deren verwendungen
DK0585570T3 (da) Granulocytbindende antistofkonstrukter, deres fremstilling og anvendelse
ATE309371T1 (de) Protein mit dnase-aktivität
NO930406D0 (no) Spesifikke antistoffer mot aktiverte blodplater samt fremstilling